Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Hepatitis D virus-induced interferon response and administered interferons control cell division-mediated virus spread
Zhenfeng Zhang, Yi Ni, Florian A. Lempp, et al.
Journal of Hepatology (2022) Vol. 77, Iss. 4, pp. 957-966
Closed Access | Times Cited: 49

Showing 1-25 of 49 citing articles:

EASL Clinical Practice Guidelines on hepatitis delta virus
Maurizia Rossana Brunetto, G. Ricco, Francesco Negro, et al.
Journal of Hepatology (2023) Vol. 79, Iss. 2, pp. 433-460
Open Access | Times Cited: 129
A Phase 3, Randomized Trial of Bulevirtide in Chronic Hepatitis D
Heiner Wedemeyer, Soo Aleman, Maurizia Rossana Brunetto, et al.
New England Journal of Medicine (2023) Vol. 389, Iss. 1, pp. 22-32
Open Access | Times Cited: 120
Hepatitis D Virus Infection
Tarik Asselah, Mario Rizzetto
New England Journal of Medicine (2023) Vol. 389, Iss. 1, pp. 58-70
Closed Access | Times Cited: 52
Bulevirtide Combined with Pegylated Interferon for Chronic Hepatitis D
Tarik Asselah, Vladimir Chulanov, Pietro Lampertico, et al.
New England Journal of Medicine (2024) Vol. 391, Iss. 2, pp. 133-143
Closed Access | Times Cited: 23
Blocking viral entry with bulevirtide reduces the number of HDV-infected hepatocytes in human liver biopsies
Lena Allweiss, Annika Volmari, Vithika Suri, et al.
Journal of Hepatology (2024) Vol. 80, Iss. 6, pp. 882-891
Open Access | Times Cited: 18
Bulevirtide monotherapy in patients with chronic HDV: Efficacy and safety results through week 96 from a phase III randomized trial
Heiner Wedemeyer, Soo Aleman, Maurizia Rossana Brunetto, et al.
Journal of Hepatology (2024) Vol. 81, Iss. 4, pp. 621-629
Open Access | Times Cited: 13
Hepatitis D virus interferes with hepatitis B virus RNA production via interferon-dependent and -independent mechanisms
Julie Lucifora, Dulce Alfaiate, Caroline Pons, et al.
Journal of Hepatology (2023) Vol. 78, Iss. 5, pp. 958-970
Open Access | Times Cited: 18
No virologic resistance to bulevirtide monotherapy detected in patients through 24 weeks treatment in phase II and III clinical trials for chronic hepatitis delta
Julius Hollnberger, Yang Liu, Simin Xu, et al.
Journal of Hepatology (2023) Vol. 79, Iss. 3, pp. 657-665
Closed Access | Times Cited: 18
Long-term follow-up of patients discontinuing bulevirtide treatment upon long-term HDV-RNA suppression
Mathias Jachs, Marlene Panzer, Lukas Hartl, et al.
JHEP Reports (2023) Vol. 5, Iss. 8, pp. 100751-100751
Open Access | Times Cited: 16
Bulevirtide in the Treatment of Hepatitis Delta: Drug Discovery, Clinical Development and Place in Therapy
Vincent Soriano, Víctor Moreno‐Torres, Ana Treviño, et al.
Drug Design Development and Therapy (2023) Vol. Volume 17, pp. 155-166
Open Access | Times Cited: 15
Hepatitis D virus infection: Pathophysiology, epidemiology and treatment. Report from the first international delta cure meeting 2022
Pietro Lampertico, Elisabetta Degasperi, Lisa Sandmann, et al.
JHEP Reports (2023) Vol. 5, Iss. 9, pp. 100818-100818
Open Access | Times Cited: 15
Advances and Challenges in Managing Hepatitis D Virus: Evolving Strategies
Harish Gopalakrishna, Maria Mironova, Harel Dahari, et al.
Current Hepatology Reports (2024) Vol. 23, Iss. 1, pp. 32-44
Open Access | Times Cited: 4
Antiviral treatment of chronic hepatitis D virus infection: To combine or not to combine?
Lisa Sandmann
Journal of Hepatology (2025)
Closed Access
Current and future therapeutic options for chronic hepatitis D virus infection
Mariantonietta Pisaturo, Giovanna Russo, Pierantonio Grimaldi, et al.
Frontiers in Cellular and Infection Microbiology (2025) Vol. 14
Open Access
A bibliometric analysis of the hepatitis D virus and its therapeutic options
Taslima Nasrin, Mehboob Hoque, Safdar Ali
Discover Viruses. (2025) Vol. 2, Iss. 1
Open Access
Single cell analysis of mature hepatocytes reveals an IRF1 driven restriction of HDV infection.
Frauke Lange, Jonathan Garn, Matthias Bruhn, et al.
JHEP Reports (2025), pp. 101429-101429
Open Access
Hepatitis D virus: Improving virological knowledge to develop new treatments
Pierre Khalfi, Patrick T. Kennedy, Karim Majzoub, et al.
Antiviral Research (2022) Vol. 209, pp. 105461-105461
Open Access | Times Cited: 16
Effect of variants in LGP2 on MDA5-mediated activation of interferon response and suppression of hepatitis D virus replication
Nadine Gillich, Zhenfeng Zhang, Marco Binder, et al.
Journal of Hepatology (2022) Vol. 78, Iss. 1, pp. 78-89
Open Access | Times Cited: 15
Treatment of Chronic Hepatitis D with Bulevirtide—A Fight against Two Foes—An Update
Péter Ferenci, Thomas Reiberger, Mathias Jachs
Cells (2022) Vol. 11, Iss. 22, pp. 3531-3531
Open Access | Times Cited: 13
Enrichment Reveals Extensive Integration of Hepatitis B Virus DNA in Hepatitis Delta Virus-Infected Patients
Johan Ringlander, Lucia Gonzales‐Siles, Joakim B. Stenbäck, et al.
The Journal of Infectious Diseases (2024) Vol. 230, Iss. 3, pp. e684-e693
Open Access | Times Cited: 2
Management of autoimmune hepatitis induced by hepatitis delta virus
Eleni Gigi, Vasileios Lagopoulos, Aris Liakos
World Journal of Gastroenterology (2024) Vol. 30, Iss. 8, pp. 799-805
Open Access | Times Cited: 2
Cell Culture Models for Hepatitis B and D Viruses Infection: Old Challenges, New Developments and Future Strategies
Arnaud Carpentier
Viruses (2024) Vol. 16, Iss. 5, pp. 716-716
Open Access | Times Cited: 2
Evaluation of the drug-drug interaction potential of the novel hepatitis B and D virus entry inhibitor bulevirtide at OATP1B in healthy volunteers
Vanessa Zhu, Jürgen Burhenne, Johanna Weiß, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 6
Hepatitis D virus infection, innate immune response and antiviral treatments in stem cell‐derived hepatocytes
Frauke Lange, Jonathan Garn, Holda A. Anagho, et al.
Liver International (2023) Vol. 43, Iss. 10, pp. 2116-2129
Open Access | Times Cited: 6
Modelling HDV kinetics under the entry inhibitor bulevirtide suggests the existence of two HDV-infected cell populations
Louis Shekhtman, Scott J. Cotler, Elisabetta Degasperi, et al.
JHEP Reports (2023) Vol. 6, Iss. 2, pp. 100966-100966
Open Access | Times Cited: 6
Page 1 - Next Page

Scroll to top